Palo Alto, Calif.-based blood testing startup Theranos submitted a plan late Friday to CMS to fix deficient practices, some of which could have put patients in "serious jeopardy," according to an update from BloombergBusiness.
CMS spokesman Aaron Albright and Theranos both confirmed the proposal was submitted, according to the report. Mr. Albright told Bloomberg CMS staff is currently reviewing the proposal.
CMS released a letter in January that summarized the deficient practices found in a November inspection at Theranos' Newark, Calif., lab, which included five major infractions for a range of issues including hematology practices, analytic systems and personnel issues. Theranos had 10 days to submit a plan of correction, and it filed for an extension earlier this month.
More articles on leadership and management:
Massachusetts General vs. Johns Hopkins: 6 key comparisons
Why the cancer 'moonshot' is not a fitting metaphor
What Justice Scalia's death could mean for healthcare: 7 things to know